MicroSectors FANG and Innovation 3X Leveraged ETN vs Medtronic PLC — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $28.94, while Medtronic PLC trades at $84.09 (market cap $103.01B). The key difference: Medtronic PLC pays a 3.58% dividend while MicroSectors FANG and Innovation 3X Leveraged ETN pays none, and MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, Medtronic PLC nearer its low. Which is the better fit depends on your goals.
| FNGU | MDT | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $36.15 | $105.35 |
52-Week Low | $13.73 | $73.75 |
Market Cap | — | $103.01B |
Enterprise Value | — | $121.75B |
Dividend Yield | — | 3.58% |
Signals from Pluang's Aura AI — not financial advice
FNGU, a 3X leveraged ETN tracking the FANG+ Index, trades at $28.77, down 0.45% on the day. The technical picture is mixed, with moving averages signaling bullish momentum but oscillators and a high RSI indicating overbought conditions. Recent news highlights the extreme volatility and decay inherent to its leveraged structure, with one report noting a $10,000 position losing 16% in a single session in June 2026.
The outlook is dominated by the product's high-risk, tactical nature. The opportunity lies in capturing amplified gains during strong bullish trends in mega-cap tech. The primary risk is significant capital erosion during volatile or sideways markets due to daily resetting leverage and compounding costs, making it unsuitable for long-term holding.
Medtronic (MDT) trades at $79.30, down 5.11% over 24 hours, with technical indicators showing bearish momentum. Fundamentally, the company reported strong earnings beats for three consecutive quarters and maintains solid profitability with a 13.2% net income margin. Recent news highlights the completion of the Scientia Vascular acquisition and bullish analyst coverage citing undervaluation and growth in cardiovascular and neuroscience segments.
The stock presents a compelling opportunity with a consensus price target of $97.50 representing 23% upside, supported by 58% analyst buy ratings. Key risks include increasing debt-to-asset ratios (31.11% in 2025) and margin pressures from tariffs and foreign exchange. The dividend aristocrat offers a near-decade high yield with consistent dividend growth.
Trailing returns across standard periods
Latest headlines on both assets
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →